Abstract | INTRODUCTION: MATERIAL AND METHODS: RESULTS: Plasma concentrations of C16-Cer, C18:1-Cer and C18-Cer were significantly higher in the advanced ovarian cancer group than in the control group (1.5-fold, p = 0.021; 1.8-fold, p = 0.036 and 1.5-fold, p = 0.031, respectively). Plasma concentration of C18:1-Cer was significantly higher in erythrocytes of women with advanced serous cancer compared to the control group (p = 0.027). Plasma C16-Cer and C18:1-Cer levels and erythrocyte C18:1-Cer levels were able to distinguish patients with moderate/severe serous ovarian cancer from patients with mild ovarian cancer (AUC: 0.86, 0.898, 0.795, respectively). Plasma concentrations of C16, C18.1 and C18 significantly correlated with FIGO staging (p = 0.001, p = 0.024 and p = 0.005), and grading (p = 0.021, p = 0.021 and p = 0.033). CONCLUSIONS: Plasma concentrations of C16, C18.1 and C18 correlated with the progression of ovarian cancer (FIGO staging and grading). Plasma levels of C16-Cer and C18:1-Cer and erythrocyte C18:1-Cer levels could be used to distinguish patients with advanced serous ovarian cancer.
|
Authors | Paweł Knapp, Lubomir Bodnar, Agnieszka Błachnio-Zabielska, Joanna Reszeć, Magdalena Świderska, Adrian Chabowski |
Journal | Archives of medical science : AMS
(Arch Med Sci)
Vol. 17
Issue 1
Pg. 53-61
( 2021)
ISSN: 1734-1922 [Print] Poland |
PMID | 33488856
(Publication Type: Journal Article)
|
Copyright | Copyright: © 2018 Termedia & Banach. |